OCRL Antibody

Code CSB-PA003502
Size US$100
Order now
Image
  • Western Blot analysis of COLO205 cells using OCRL Polyclonal Antibody
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
OCRL
Alternative Names
EC 3.1.3.36 antibody; Inositol polyphosphate 5 phosphatase OCRL 1 antibody; Inositol polyphosphate 5 phosphatase OCRL1 antibody; Inositol polyphosphate 5-phosphatase OCRL-1 antibody; INPP5F antibody; LOCR antibody; Lowe oculocerebrorenal syndrome protein antibody; NPHL2 antibody; OCRL 1 antibody; OCRL antibody; OCRL_HUMAN antibody; OCRL1 antibody; Oculocerebrorenal syndrome of Lowe antibody; Phosphatidylinositol polyphosphate 5 phosphatase antibody
Raised in
Rabbit
Species Reactivity
Human,Mouse
Immunogen
Synthesized peptide derived from the Internal region of Human OCRL.
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Isotype
IgG
Purification Method
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Form
Liquid
Tested Applications
WB, ELISA
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:2000
ELISA 1:10000
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Catalyzes the hydrolysis of the 5-position phosphate of phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) and phosphatidylinositol-3,4,5-bisphosphate (PtdIns(3,4,5)P3), with the greatest catalytic activity towards PtdIns(4,5)P2. Able also to hydrolyze the 5-phosphate of inositol 1,4,5-trisphosphate and of inositol 1,3,4,5-tetrakisphosphate. Regulates traffic in the endosomal pathway by regulating the specific pool of phosphatidylinositol 4,5-bisphosphate that is associated with endosomes. Involved in primary cilia assembly. Acts as a regulator of phagocytosis, hydrolyzing PtdIns(4,5)P2 to promote phagosome closure, through attenuation of PI3K signaling.
Gene References into Functions
  1. Study has identified two novel mutations in two unrelated Lowe syndrome patients with congenital glaucoma. Novel deletion mutations are detected at c.739-742delAAAG in Lowe patient 1 and c.1595-1631del in Lowe patient 2. PMID: 28473699
  2. OCRL mutation is associated with progressive chronic kidney disease. PMID: 27708066
  3. loss of OCRL results in abnormal distribution of PI(4,5)P2 in the proximal regions of cilia. PMID: 28871046
  4. patients with OCRL-1 mutations or type 1 Dent disease showed abnormally low levels of urinary A-megalin PMID: 27766457
  5. OCRL1 gene mutation is responsible in the development od Lowe syndrome in Chinese families. PMID: 27059748
  6. docrl ( phosphatidylinositol-5-phosphatase OCRL)regulation of endosomal traffic maintains hemocytes in a poised, but quiescent state, suggesting mechanisms by which endosomal misregulation of signaling may contribute to symptoms of Lowe syndrome PMID: 29028801
  7. We discuss how studies of OCRL have led to important discoveries about the basic mechanisms of membrane trafficking and describe the key features and limitations of the currently available animal models of Lowe syndrome. Mutations in OCRL can also give rise to a milder pathology, Dent disease 2, which is characterized by renal Fanconi syndrome in the absence of extrarenal pathologies. PMID: 28669993
  8. A diagnosis of Dent disease was established in 19 boys from 16 families by the presence of loss of function/deleterious mutations in CLCN5 or OCRL1. PMID: 27174143
  9. Depleting or inhibiting OCRL leads to an accumulation of lysosomal PtdIns(4,5)P2, an inhibitor of the calcium channel mucolipin-1 that controls autophagosome-lysosome fusion PMID: 27398910
  10. Here we show that OCRL1 is part of the membrane-trafficking machinery operating at the trans-Golgi network (TGN)/endosome interface. PMID: 26510499
  11. Authors propose that the precise spatial and temporal activation of Rab35 acts as a major switch for OCRL recruitment on newborn endosomes, post-scission PtdIns(4,5)P2 hydrolysis, and subsequent endosomal trafficking. PMID: 26725203
  12. OCRL mRNA and protein were downregulated in osteoarthritis knee cartilage. OCRL inhibits Rac1 activation in OA. PMID: 25917196
  13. OCRL-mutated fibroblasts from patients with Dent-2 disease exhibit INPP5B-independent phenotypic variability relatively to Lowe syndrome cells. PMID: 25305077
  14. Results indicate that inositol 5-phosphatase OCRL acts as an uncoating factor and that defects in clathrin-mediated endocytosis likely contribute to pathology in patients with OCRL mutations. PMID: 25107275
  15. The crystal structures of human OCRL in complex with phosphoinositide substrate analogs revealed a membrane interaction patch likely to assist in sequestering substrates from the lipid bilayer. PMID: 24704254
  16. Implications of OCRL and TRPV4 in primary cilia function may also shed light on mechanosensation in other organ systems. PMID: 25143588
  17. Dent disease is caused by mutations in at least two genes, i.e. CLCN5 and OCRL1, and its genetic background and phenotypes are common among European countries and the USA. PMID: 24081861
  18. Three Chinese children were diagnosed with Lowe syndrome through clinical and genetic analyses. And two novel mutations in the OCRL gene were identified PMID: 23389333
  19. a role of OCRL in cilia maintenance and suggest the involvement of ciliary dysfunction in the manifestation of Lowe syndrome. PMID: 22543976
  20. The 5-phosphatase OCRL mediates retrograde transport of the mannose 6-phosphate receptor by regulating a Rac1-cofilin signalling module. PMID: 22907655
  21. This article reviewes biophysical and structural work and discuss possible functional implications of the finding that Rab8 binds with the highest affinity to OCRL1 among the Rab proteins tested.[review] PMID: 22790198
  22. In our study of 187 probands with autism, we have identified a duplication in Xq25 including full gene duplication of OCRL and six flanking genes. PMID: 22965764
  23. Bcl10 was required to locally deliver the vesicular OCRL phosphatase that regulates PI(4,5)P(2) and F-actin turnover, both crucial for the completion of phagosome closure. PMID: 23153494
  24. All seven Dent-causing OCRL mutations examined exhibited alleviation of the inhibitory effect on TRPV6-mediated Ca(2+) transport. PMID: 22378746
  25. A recurrent OCRL nonsense mutation was found to be the pathogenic mutation in a Chinese family with Lowe syndrome. PMID: 22177125
  26. Through its phosphatase activity, OCRL restricts Listeria monocytogenes invasion by modulating actin dynamics at bacterial internalization sites. PMID: 22351770
  27. Lowe syndrome displays characteristics of a ciliopathy; findings reveal a novel cellular role for Ocrl1 in cilia assembly -- Ocrl1 participates in ciliogenesis by contributing to protein trafficking to this organelle in an Rab8/IPIP27-dependent manner PMID: 22228094
  28. Novel nonsense mutation (c.880G>T) in exon 10 and the novel insertion mutation (c.2626dupA) in exon 24 of the OCRL1 gene lead to Lowe syndrome in two Chinese families. PMID: 21854507
  29. A role of OCRL1 in junctions of polarized cells may explain the pattern of organs affected in Lowe Syndrome. PMID: 21901156
  30. via its 5-phosphatase activity, OCRL controls early endosome function. PMID: 21971085
  31. the phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2) 5-phosphatase OCRL, which is mutated in Lowe syndrome patients, is an effector of the Rab35 GTPase in cytokinesis abscission PMID: 21706022
  32. The phenylalanine and histidine (F&H) motif binding site on the RhoGAP domain of OCRL was identified. PMID: 21666675
  33. From Lowe syndrome to Dent disease: correlations between mutations of the OCRL1 gene and clinical and biochemical phenotypes PMID: 21031565
  34. These data suggest that the mutations observed in OCRL are the result of two de novo events in early embryogenesis of the mother. PMID: 21225285
  35. OCRL1 mutation is associated with Lowe syndrome. PMID: 21378754
  36. Two novel OCRL1-binding proteins, termed inositol polyphosphate phosphatase interacting protein of 27 kDa (IPIP27)A and B (also known as Ses1 and 2), that also bind the related 5-phosphatase Inpp5b, were identified. PMID: 21233288
  37. children with OCRL mutations may present with very mild phenotype (asymptomatic proteinuria with/without mild mental retardation) or severe classic oculocerebrorenal syndrome of Lowe PMID: 21249396
  38. evidence for link between OCRL mutations and primary haemostasis disorders in Lowe syndrome; findings suggests that an aberrant RhoA pathway in platelets contributes to CT prolongation and primary haemostasis disorders in Lowe syndrome PMID: 20629659
  39. This multiplex ligation-dependent probe amplification allows rapid and precise OCRL1 gene quantification. PMID: 20043897
  40. Two closely related endocytic proteins, Ses1 and Ses2, which interact with OCRL, were identified. The interaction is mediated by a short amino acid motif similar to that used by the rab-5 effector APPL1. PMID: 20133602
  41. OCRL1 does not directly modulate endocytosis or postendocytic membrane traffic, and renal manifestations observed in Lowe syndrome patients are downstream consequences of loss of OCRL1 function. PMID: 19940034
  42. The homologous phosphatase Inpp5b was unable to complement the Ocrl1-dependent cell migration defect. PMID: 19700499
  43. Studies showed that three novel CLC-5 mutations were identified, and mutations in OCRL1, CLC-4 and cofilin excluded in causing Dent's disease. PMID: 19546591
  44. The deficiency of PIP2 5-phosphatase in Lowe syndrome affects actin polymerization PMID: 12428211
  45. OCRL1 interacts with Rac GTPase in the trans-Golgi network. PMID: 12915445
  46. suggests that Ocrl1 is active as a PIP2 5-phosphatase in Rac induced membrane ruffles PMID: 15829501
  47. OCRL1 is associated with clathrin-coated transport intermediates operating between the trans-Golgi network (TGN) and endosomes PMID: 15917292
  48. p.Phe259Ser mutation found in a case of Lowe syndrome (amino acid substitution) PMID: 16420990
  49. rabs play a dual role in regulation of OCRL1, firstly targeting it to the Golgi apparatus and endosomes, and secondly, directly stimulating the 5-phosphatase activity of OCRL1 after membrane recruitment. PMID: 16902405
  50. One frame shift mutation and two misssense mutations were identified in three male patients with the Dent disease phenotype. PMID: 17384968

Show More

Hide All

Involvement in disease
Lowe oculocerebrorenal syndrome (OCRL); Dent disease 2 (DD2)
Subcellular Location
Cytoplasmic vesicle, phagosome membrane. Early endosome membrane. Membrane, clathrin-coated pit. Cell projection, cilium, photoreceptor outer segment. Cell projection, cilium. Cytoplasmic vesicle. Endosome. Golgi apparatus, trans-Golgi network. Lysosome.
Protein Families
Inositol 1,4,5-trisphosphate 5-phosphatase type II family
Tissue Specificity
Brain, skeletal muscle, heart, kidney, lung, placenta and fibroblasts. Expressed in the retina and the retinal pigment epithelium.
Database Links

HGNC: 8108

OMIM: 300535

KEGG: hsa:4952

STRING: 9606.ENSP00000360154

UniGene: Hs.126357

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalization X
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*